表紙
市場調査レポート

EpiCast Report:筋萎縮性側索硬化症(ALS)の疫学的予測

EpiCast Report: Amyotrophic Lateral Sclerosis - Epidemiology Forecast to 2023

発行 GlobalData 商品コード 301139
出版日 ページ情報 英文 38 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
EpiCast Report:筋萎縮性側索硬化症(ALS)の疫学的予測 EpiCast Report: Amyotrophic Lateral Sclerosis - Epidemiology Forecast to 2023
出版日: 2014年05月01日 ページ情報: 英文 38 Pages
概要

筋萎縮性側索硬化症(ALS)はルー・ゲーリック病とも呼ばれる進行性の神経変性疾患で、脳や脊椎の神経細胞に悪影響を及ぼします。ALSは身体機能に深刻な影響を与え、その初期段階では、筋攣縮や腕部・脚部の弱体化、ろれつが回らないといった症状が生じます。その後、ALS患者は段階的に、移動・会話・食事・呼吸に必要な筋肉を制御する能力を失っていき、最後には死に至ります。身体能力の段階的な後退という症状は、患者と介護者の双方、また社会全体にとっての重い負担となっています。世界の主要7ヶ国におけるALSの診断済み有病者数は、2013年の32,698人から、2023年には37,122人にまで増加する、と予想されています(増加率13.5%)。国別では米国が最大の患者数を抱え、にほんがそれに続いています。

当レポートでは、世界の主要7ヶ国(米国・フランス・ドイツ・イタリア・スペイン・英国・日本)における筋萎縮性側索硬化症(ALS)の発症状況や今後の見通しについて分析し、疾患の特徴(リスク要因や主な共存症など)や世界各国での動向、現在の有病者の発症状況、今後10年間の発症・有病件数の予測値などを調査・推計して、その結果を概略以下の内容でお届けいたします。

第1章 目次

第2章 イントロダクション

  • 概要
  • 近日刊行の関連調査

第3章 疫学

  • 疾患の背景
  • リスク要因と共存症
  • 世界的な傾向
    • 米国
    • 欧州5ヶ国
    • 日本
  • 予測手法
    • 利用した情報源
    • 利用しなかった情報源
    • 予測の前提条件と手法:
  • 筋萎縮性側索硬化症(ALS)の疫学予測(今後11年間分)
    • 診断された有病者数
    • 診断された有病者数(年齢別)
    • 診断された有病者数(性別)
    • 診断された有病者数(年齢調整済み)
  • 議論
    • 疫学的な予測に関する結論
    • 分析の限界
    • 分析の強み

第4章 付録

図表一覧

目次
Product Code: GDHCER063

Amyotrophic lateral sclerosis (ALS), often referred to as "Lou Gehrig's Disease," is a rare, but fatal, progressive neurodegenerative disease that affects the nerve cells in the brain and the spinal cord. ALS severely impacts physical functioning and initially presents with muscle twitching, weakness in an arm or leg, or with slurring of speech. Eventually, people with ALS lose their ability to control the muscles needed to move, speak, eat, and breathe, which ultimately leads to death. The progressively degenerative course of the condition is a great burden for both patients and caregivers, as well as for society.

GlobalData epidemiologists forecast that the diagnosed prevalent cases of ALS in the 7MM will grow by 13.5% over the next decade, from 32,698 diagnosed prevalent cases in 2013 to 37,122 diagnosed prevalent cases in 2023. Throughout the forecast period, the US will have the highest numbers of diagnosed prevalent cases of ALS, followed by Japan.

To develop the epidemiological forecast for the diagnosed prevalent cases of ALS in the 7MM, GlobalData epidemiologists obtained the diagnosed prevalence data for ALS from peer-reviewed journals and population-based studies in the respective markets and used a consistent methodology to ensure comparability of the results. A major strength of GlobalData's epidemiological analysis is the use of country-specific studies that provided the diagnosed prevalence of ALS using uniform diagnostic criteria based on the El Escorial criteria or the International Classification of Diseases, Ninth Revision (ICD-9), criteria (ICD-9 code for ALS = 335.2), to allow for a meaningful comparison of the diagnosed prevalent cases of ALS in these markets. Furthermore, the diagnosed prevalent cases of ALS in each of the 7MM were further segmented by age and sex in order to provide a more detailed analysis of the patient population.

Scope

  • The Amyotrophic lateral sclerosis (ALS) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for ALS in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of ALS segmented by age (=40 years) and sex in these markets.
  • The ALS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global ALS market.
  • Quantify patient populations in the global ALS market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for ALS therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
    • 3.3.3. Japan
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for Amyotrophic Lateral Sclerosis (2013-2023)
    • 3.5.1. Diagnosed Prevalent Cases of ALS
    • 3.5.2. Age-Specific Diagnosed Prevalent Cases of ALS
    • 3.5.3. Sex-Specific Diagnosed Prevalent Cases of ALS
    • 3.5.4. Age-Standardized Diagnosed Prevalence of ALS
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Epidemiology and Health Policy
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for ALS
  • Table 2: Incidence (Cases per 100,000 Population) of ALS in the US, as Reported in Epidemiological Studies
  • Table 3: Prevalence (Cases per 100,000 Population) of ALS in the US, as Reported in Epidemiological Studies
  • Table 4: Incidence (Cases per 100,000 Population) of ALS in the European Markets, as Reported in Epidemiological Studies
  • Table 5: Prevalence (Cases per 100,000 Population) of ALS in the European Markets, as Reported in Epidemiological Studies
  • Table 6: El Escorial Diagnostic Criteria for ALS
  • Table 7: 7MM, Sources of Diagnosed Prevalence Data Used to Forecast the Diagnosed Prevalent Cases of ALS
  • Table 8: 7MM, Diagnosed Prevalent Cases of ALS, Age ≥40 Years, Both Sexes, N, 2013-2023
  • Table 9: 7MM, Diagnosed Prevalent Cases of ALS, by Age, Both Sexes, N, (Row %), 2013
  • Table 10: 7MM, Diagnosed Prevalent Cases of ALS, by Sex, Age ≥40 years, N (Row %), 2013

List of Figures

  • Figure 1: 7MM, Diagnosed Prevalent Cases of ALS, Age ≥40 Years, Both Sexes, N, 2013-2023
  • Figure 2: 7MM, Diagnosed Prevalent Cases of ALS, by Age, Both Sexes, N, 2013
  • Figure 3: 7MM, Diagnosed Prevalent Cases of ALS, by Sex, Age ≥40 Years, N, 2013
  • Figure 4: 7MM, Age-Standardized Diagnosed Prevalence (%) of ALS, Age ≥40 Years, 2013
Back to Top